ClinVar Miner

Submissions for variant NM_033629.6(TREX1):c.290G>A (p.Arg97His)

gnomAD frequency: 0.00003  dbSNP: rs200773268
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Soonchunhyang University Bucheon Hospital, Soonchunhyang University Medical Center RCV000490435 SCV000267537 likely pathogenic Aicardi-Goutieres syndrome 1 2016-03-18 criteria provided, single submitter reference population
CeGaT Center for Human Genetics Tuebingen RCV001093075 SCV001249887 pathogenic not provided 2018-05-01 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000490435 SCV002050828 likely pathogenic Aicardi-Goutieres syndrome 1 2021-12-08 criteria provided, single submitter clinical testing Variant summary: TREX1 c.290G>A (p.Arg97His) results in a non-conservative amino acid change in the encoded protein sequence. Three of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6e-05 in 249418 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in TREX1 causing Aicardi Goutieres Syndrome 1 (6e-05 vs ND), allowing no conclusion about variant significance. c.290G>A has been reported in the literature in individuals affected with Aicardi Goutieres Syndrome 1 (compound heterozygote, Olivieri_2013) or affected with cerebral lupus (homozygote, Ellyard_2014). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (Ellyard_2014). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Invitae RCV001853392 SCV002123015 pathogenic Aicardi-Goutieres syndrome 1; Chilblain lupus 1; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations 2024-01-29 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 97 of the TREX1 protein (p.Arg97His). This variant is present in population databases (rs200773268, gnomAD 0.02%). This missense change has been observed in individual(s) with autosomal recessive Aicardi-Goutieres syndrome and/or systemic lupus erythematosus (PMID: 3580372, 23918923, 25138095, 31130681, 34490615, 35803721). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 225498). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects TREX1 function (PMID: 22367235, 25138095). For these reasons, this variant has been classified as Pathogenic.
Revvity Omics, Revvity RCV001093075 SCV003823461 uncertain significance not provided 2020-10-26 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.